NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...
Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...
A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.
If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.
AstraZeneca PLC AZN shares inched down 0.11% to £110.40 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13.
Bearish flow noted in AstraZeneca (AZN) with 1,547 puts trading, or 1.9x expected. Most active are 2/14 weekly 68 puts and Feb-25 70 puts, with ...
President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.